Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of omega-3 fatty acids supplementation compared with the placebo on levels of gene expression related with glycemic control and inflammatory factors in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201606115623N83

Enrollment

Registered

2016-06-15

Start date

2016-04-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 1000 mg omega-3 fatty acids (Barij Essence, Kashan, Iran), twice a day, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), t

Treatment - Drugs

Intervention group: 1000 mg omega-3 fatty acids (Barij Essence, Kashan, Iran), twice a day, for 12 weeks orally.

Control group: Placebo (Barij Essence, Kashan, Iran), twice a day, for 12 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with PCOS according to Rotterdam criteria; aged 18 to 40 years. Exclusion criteria: Unwillingness to cooperate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Expressed levels of TNFa gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-6 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of TNFa gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-6 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026